CordenPharma to Expand Lipid Purification Capacity at its Colorado Site
CordenPharma’s expansion will include the addition of new production lines which will be merged into the lipid manufacturing process in April 2021.
CordenPharma announced on April 19, 2021 that it is expanding its lipid purification capacity at its Colorado site.
According to a CordenPharma press release, the expansion will include the addition of new production lines, which will be merged into the lipid manufacturing process in April 2021. By July 2021, the company expects a decrease in lipid shipment delivery time due to the expansion.
“CordenPharma is proud to contribute this major capital expansion to increase important lipid production for the global market,” said Michael Quirmbach, CEO and president, CordenPharma. “We have drawn upon longstanding expertise in specialized lipids to create an even stronger integrated network of facilities to support current and future projects.”
The company, who has also expanded its lipid supply chain at its facilities in Switzerland and France, manufactures four lipids used to formulate messenger RNA (mRNA)-based vaccines. They include:
- Cationic lipids that condense negatively charged mRNA
- PEGylated lipids that form a protective hydrophilic layer, which sterically stabilizes the lipid nanoparticle (LNP)
- DiStearoylphosPhatidylCholine (DSPC), a phospholipid that offers a stable bilayer-forming structure
- Plant-based cholesterol (CP BotaniChol), which stabilizes the LNP structures and enables endosome escape.
Source: CordenPharma
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
